The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial: Clinical article
Abstract
Object: Delayed ischemic deficits (DIDs), a major source of disability following aneurysmal subarachnoid hemorrhage (aSAH), are usually associated with severe cerebral vasospasm and impaired autoregulation. Systemic erythropoietin (EPO) therapy has been demonstrated to have neuroprotective properties acting via EPO receptors on cerebrovascular endothelia and ischemic neurons. In this trial, the authors explored the potential neuroprotective effects of acute EPO therapy following aSAH. Methods: Within 72 hours of aSAH, 80 patients (age range 24–82 years) were randomized to receive intravenous EPO (30,000 U) or placebo every 48 hours for a total of 90,000 U. Primary end points were the incidence, duration, and severity of vasospasm and impaired autoregulation on transcranial Doppler ultrasonography. Secondary end points were incidence of DIDs and outcome at discharge and at 6 months. Results: Randomization characteristics were balanced except for age, with the EPO group being older (mean age 59.6 vs 53.3 years, p = 0.034). No differences were demonstrated in the incidence of vasospasm and adverse events; however, patients receiving EPO had a decreased incidence of severe vasospasm from 27.5 to 7.5% (p = 0.037), reduced DIDs with new cerebral infarcts from 40.0 to 7.5% (p = 0.001), a shortened duration of impaired autoregulation (ipsilateral side, p < 0.001), and more favorable outcome at discharge (favorable Glasgow Outcome Scale score, p = 0.039). Among the 71 survivors, the EPO group had fewer deficits measured with National Institutes of Health Stroke Scale (median Score 2 vs 6, p = 0.008). Conclusions: This preliminary study showed that EPO seemed to reduce delayed cerebral ischemia following aSAH via decreasing severity of vasospasm and shortening impaired autoregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale
JENNETT, B. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92830-5 · Cited by 7,501
Cited by
Delayed neurological deterioration after subarachnoid haemorrhage
Macdonald, R. L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.246 · Cited by 887
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Aneurysmal Subarachnoid Hemorrhage: the Last Decade
Neifert, S. N., Chapman, E. K., Martini, M. L., Shuman, W. H., Schupper, A. J., Oermann, E. K., Mocco, J., & Macdonald, R. L. (2021) · Translational Stroke Research · doi:10.1007/s12975-020-00867-0 · Cited by 424
Management of delayed cerebral ischemia after subarachnoid hemorrhage
Francoeur, C. L., & Mayer, S. A. (2016) · Critical Care · doi:10.1186/s13054-016-1447-6 · Cited by 388
Jaja, B. N. R., Saposnik, G., Lingsma, H. F., Macdonald, E., Thorpe, K. E., Mamdani, M., Steyerberg, E. W., Molyneux, A., Manoel, A. L. D. O., Schatlo, B., et al. (2018) · BMJ · doi:10.1136/bmj.j5745 · Cited by 268
Self-citation
Metadata
- Authors
- Tseng, M.-Y., Hutchinson, P. J., Richards, H. K., Czosnyka, M., Pickard, J. D., Erber, W. N., Brown, S., & Kirkpatrick, P. J.
- Venue
- Journal of Neurosurgery
- Published
- 2009-07
- Volume
- 111
- Issue
- 1
- Pages
- 171-180
- ISSN
- 0022-3085 (ISSN-L)
- 1933-0693
- OpenAlex
- W1979804841
- Cited by
- 171
- References
- 1
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial: Clinical article. https://app.cochat.ai/papers/10.3171/2009.3.jns081332
- The paper
- Tseng, M.-Y., Hutchinson, P. J., Richards, H. K., Czosnyka, M., Pickard, J. D., Erber, W. N., Brown, S., & Kirkpatrick, P. J. (2009). Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial: Clinical article. Journal of Neurosurgery. https://doi.org/10.3171/2009.3.jns081332
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.